Provided by Tiger Trade Technology Pte. Ltd.

Lantern Pharma Inc.

2.34
+0.05002.18%
Post-market: 2.380.0400+1.71%19:30 EDT
Volume:185.08K
Turnover:427.98K
Market Cap:29.86M
PE:-1.43
High:2.41
Open:2.32
Low:2.13
Close:2.29
52wk High:4.70
52wk Low:1.11
Shares:12.76M
Float Shares:10.14M
Volume Ratio:1.23
T/O Rate:1.83%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.6362
EPS(LYR):-1.5709
ROE:-400.92%
ROA:-74.29%
PB:-9.28
PE(LYR):-1.49

Loading ...

Lantern Pharma to debut withZeta.ai at Nasdaq investor briefing

Reuters
·
Apr 14

Lantern Pharma Showcases withZeta.ai Platform for Rare Cancers

TIPRANKS
·
Apr 10

Lantern Pharma to host live demonstration of withZeta.ai

TIPRANKS
·
Apr 02

Lantern Pharma to host investor webcast featuring live demo of withZeta.ai platform

Reuters
·
Apr 02

Lantern Pharma Reports 2025 Results and Pipeline Progress

TIPRANKS
·
Mar 31

Lantern Pharma: to Offer Shares of Common Stock on Best Efforts Basis; Size Not Disclosed - SEC Filing

THOMSON REUTERS
·
Mar 31

Lantern Pharma Q4 EPS $(0.36) Beats $(0.46) Estimate

Benzinga Earnings
·
Mar 31

Lantern Pharma says article on CEO leaving ‘false and misleading’

TIPRANKS
·
Mar 31

Lantern Pharma FY25 net loss narrows 18% to $17M

Reuters
·
Mar 31

Press Release: Lantern Pharma Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

Dow Jones
·
Mar 31

Why Is Lantern Pharma Stock Soaring Monday?

Benzinga_recent_news
·
Mar 30

Lantern Pharma Inc: Intends to Pursue All Available Legal Remedies and Is Considering Referring This Matter to the Appropriate Regulatory Authorities

THOMSON REUTERS
·
Mar 28

Lantern Pharma Confirms Panna Sharma Continues to Serve as President and CEO; Alerts Investors to False Third-Party Report

THOMSON REUTERS
·
Mar 28

Lantern Pharma says CEO Panna Sharma remains in role; company warns investors about false third-party report

Reuters
·
Mar 28

Lantern Pharma Inc expected to post a loss of 46 cents a share - Earnings Preview

Reuters
·
Mar 28

BUZZ-U.S. STOCKS ON THE MOVE-Entergy, IDEX Corp, Quanta Services

Reuters
·
Mar 27

BUZZ-Lantern Pharma up after FDA allows trial of pediatric brain cancer drug

Reuters
·
Mar 27

Lantern Pharma Shares up 11.5% Premarket After Receiving FDA Clearance to Start Child Brain Cancer Treatment Study

THOMSON REUTERS
·
Mar 27

Lantern Pharma rises; FDA clears IND No. 179145 for STAR-001 Phase 1 pediatric CNS cancer trial

Reuters
·
Mar 27

Lantern Pharma and Starlight Therapeutics Announce FDA Clearance of Ind for a Planned Phase 1 Pediatric CNS Cancer Trial of Star-001

THOMSON REUTERS
·
Mar 27